The global Single Cell Analysis Market was valued at USD 2.9 Billion in 2022 and is projected to reach USD 9.06 Billion by 2030, growing at a CAGR of 15.3% from 2023 to 2030.
Single Cell Analysis Market Overview:
Single-cell analysis (SCA) is very important for showing how different a population is, finding interesting minority subpopulations, and finding out what makes each cell unique. Microfluidic platforms for single-cell analysis work on a scale similar to the size of a cell and can be used to manipulate single cells. A microfluidic trapping array that can quickly and reliably catch a single cell in a group of microwells that are very close together. Since the design of the channels, not the flow rate, determines how well single cells can be trapped, this trapping array can be connected to different microfluidic sample processing units with different flow rates to do different types of single-cell analyses. SCA is also used a lot in immunology, microbiology, neurobiology, prenatal diagnosis, embryogenesis, and plant biology, among other fields.
During the forecast period, the global demand for single cell analysis is expected to grow. This is because the technology for single cell analysis is getting better, and the pharmaceutical and biotechnology industries are doing more research and development, which also helps the growth of the single cell analysis market. The single cell analysis market is also growing because stem cell research is getting bigger, personalised medicine is getting more attention, and the number of people getting cancer is going up. But the high cost of products for analysing a single cell is likely to slow the growth of the market. During the single cell analysis market forecast, the high growth potential of single cell sequencing is expected to provide lucrative growth opportunities for the key player in the market.
Growing prevalence of cancer
Cancer genomics is one of the most important ways that single-cell analysis is used. GLOBOCAN says that there will be about 30 million new cases of cancer by 2040, up from 19.3 million cases and 10 million cancer deaths in 2020. Because this disease is becoming more common, more research is needed to figure out how to diagnose and treat it. Single-cell analysis is an important part of this research. The correct diagnosis of diseases and the effectiveness of treatments can be made by looking at individual cells. Single-cell analysis helps count the number of helper T-cells, find out how much DNA is in a cell, and track the growth of tumour cells in breast cancer and other cancers.
High cost of single-cell analysis products
Single-cell biology research is expensive because it needs to keep high-quality standards (by using high-quality, expensive products) and follow rules set by regulatory authorities. But research and academic labs can't always afford to buy such expensive equipment because their budgets are limited. The total cost of owning these instruments goes up because of the costs of maintenance and a number of other indirect costs. This is a big reason why flow cytometers and microfluidic devices aren't used more in both clinical and research settings.
High growth potential of single-cell sequencing
Single-cell sequencing is thought to be a powerful way to find disease-specific biomarkers that can be used to diagnose and track the onset, progression, and response to the treatment of a disease. Since SCS gives a lot of information about genetic mutations, companies are working on making instruments and chemicals that can be used with single-cell sequencers. Because this market segment has a lot of room to grow, many new, advanced SCS instruments are likely to be made and put on the market in the next few years.
Single Cell Analysis Market Segmentation Analysis
By product, The single-cell analysis market is split into consumables and instruments based on what they are used for. The consumables segment has the largest market share and the highest CAGR. This is expected to continue during the forecast period because the products are easy to use and reagents need to be bought often, the number of target diseases is rising, and consumables are always needed for the assay.
By Technique, the market is split into flow cytometry, next-generation sequencing, polymerase chain reaction, mass spectrometry, and others. The next-generation sequencing segment brought in the most revenue in 2021 and is expected to keep doing so during the forecast period. This is due to an increase in genome mapping programs, a rise in next-generation sequencing applications, an increase in healthcare spending, and technological improvements in sequencing platforms, all of which are driving the segment growth.
By Application, the market is divided into oncology, immunology, neurology, stem cell, non-invasive prenatal diagnosis, in-vitro fertilization, and others. The oncology segment brought in the most money in 2021, and because cancer is becoming more common, this is likely to stay the case during the forecast period. Also, single-cell analysis worked well for diagnosing cancer cells in the past, which helped the segment grow.
By End user, The market is divided into academic and research labs, biotechnology and pharmaceutical companies, hospitals and diagnostic labs, cell banks, and IVF centers, based on who will use the products. The biotechnology and pharmaceutical companies segment had the largest share of the single-cell analysis market in 2021, and this trend is expected to continue over the next few years. This is because technological advances, such as the use of microfluidics in the development of next-generation therapies, have made biotechnology and pharmaceutical companies more likely to use single-cell analysis.
During the Forecast period, North America is anticipated to be the largest market by region.
In 2021, North America had more than 35.0% of the world's market revenue. This is because of things like the government's many funding programmes, people's growing awareness of their own health and the costs associated with it, the faster adoption of new analytical tools and techniques, and the availability of trained staff. North American business growth is helped a lot by the U.S. For example, the U.S. National Institutes of Health (NIH) supports metabolomics research through its Common Fund Programs. Before, the NIH also used the same funds to pay for the Single Cell Analysis Program (SCAP). Some of the main things that are driving growth in the region are an excellent healthcare infrastructure, the need for personalised medicines, and the presence of key market players.
During the time frame of the forecast, the Asia-Pacific market is expected to grow at a CAGR of 13.2%. In the past few years, the demand for cutting-edge diagnostic tools in the emerging economies of Asia Pacific has been fueled by a growing medical industry, quickly improving health care systems, and a growing number of older people. Focused work and outsourcing have led to a lot of growth in this area.
- In March 2021, Beckman Coulter (a subsidiary of Danaher Corporation) introduced the CytoFLEX SRT benchtop sorter featuring expanded laser and color options for labs of all sizes.
- In March 2020, Fluidigm Corporation (USA) opened a new Center of Excellence (CoE) for Imaging Mass Cytometry (IMC) in Singapore with the Singapore Immunology Network (SIgN), part of the Science, Technology and Research Organization.
- In November 2019, Qiagen launched a new workflow called QiaSeq Multimodal Panels for real-time preparation of DNA and RNA libraries for next-generation sequencing.
The Global Single Cell Analysis Market has been segmented into:
- Flow Cytometers
- NGS Systems
- PCR Instruments
- Flow Cytometry
- Next Generations Sequencing
- Polymerase Chain Reaction
- Mass Spectrometry
- Stem cell
- Non-invasive prenatal diagnosis
- In-vitro fertilization
By End User
- Academic & Research Laboratories
- Biotechnology & Pharmaceutical Companies
- Hospitals & Diagnostic Laboratories
- BectonDickinson and Company (US)
- Danaher Corporation (US)
- Merck KGAA (Germany)
- QIAGEN N.V. (Netherlands)
- Thermo Fisher ScientificInc. (US)
- 10x Genomics (US)
- Promega Corporation (US)
- Bio-Rad Laboratories (US)
- Fluidigm Corporation (US)
- Agilent TechnologiesInc. (US)
- Tecan Group Ltd. (Switzerland)
- Sartorius AG (Germany)
- Luminex Corporation (US)
- Takara Bio (Japan)
- Fluxion Biosciences (US)
- Menarini Silicon BiosystemsInc. (Italy)
- bioMérieux SA (France)
- Oxford Nanopore Technologies (UK)
- Cytek Biosciences (US)
- Corning Incorporated (US)
- Apogee Flow Systems Ltd. (UK)
- NanoCellect Biomedical (US)
- Rarecyte Inc (US)
- On-chip Biotechnologies Co.Ltd. (Japan).